Drug Approval | September 06, 2024
Strides receive USFDA approval for Theophylline ER tablets, 300 mg and 450 mg
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug
Chobhe brings over 30 years of extensive experience in quality and regulatory management within the pharmaceutical industry
Also received tentative approval for 137 mg
The new Injectable Facility housed in Akums Healthcare started commercial production on 22nd August 2024, with a capacity of 362 million units annually
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
This project is supported by the Irish Government through IDA Ireland
Subscribe To Our Newsletter & Stay Updated
